We can outgrow biosimilar erosion curve,' Roche leaders tell anxious investors

5 February 2018
biosimilars_samples_large

While the likes of Amgen (Nasdaq: AMGN) and Johnson & Johnson (NYSE: JNJ) have already started to take the hit from competitors to big-selling biologics, looking ahead to the next two to three years, it is unlikely that the specter of biosimilars hangs over any company more than Roche (ROG: SIX).

So it is no wonder that executives of the Swiss pharma giant referred frequently to their confidence that the company can replace the revenue lost to these competitors when speaking to investors on Thursday, as well as reminding them that they had received a remarkable 31st consecutive annual dividend increase.

Daniel O’Day, chief executive of Roche Pharmaceuticals, said: “No other company has had to withstand such significant patent erosion and said “we have the confidence to grow through it.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars